Interventions: Alternate-day S-1 (80mg/m2; day 2,4,6...14) combined with irinotecan (150mg/m2; day 1) and bevacizumab (5.0 mg/kg; day 1) Primary outcome(s): Incidence of grade 3 or 4 diarrhea Study De
Supplementary Table 1: Most common cutaneous adverse events observed in patients with vascular anomalies taking MEK-inhibitors, excluding patients on concurrent therapies.
BackgroundThis study aims to assess the adverse events (AEs) and safety profile of omeprazole, a widely used proton pump inhibitor (PPI) for acid-related diseases. Despite being a first-line treatment
